Estonya - Estonca - Ravimiamet

noucor health s.a. - rupatadiin - suukaudne lahus - 1mg 1ml 120ml 1tk

Estonya - Estonca - Ravimiamet

ntc s.r.l. - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 3viaal; 50mcg 1ml 2.5ml 1viaal

Estonya - Estonca - Ravimiamet

mylan ireland limited - posakonasool - suukaudne suspensioon - 40mg 1ml 105ml 1tk

Estonya - Estonca - Ravimiamet

stada arzneimittel ag - timolool+travoprost - silmatilgad, lahus - 5mg+40mcg 1ml 2.5ml 3tk; 5mg+40mcg 1ml 2.5ml 6tk

Estonya - Estonca - Ravimiamet

stada arzneimittel ag - timolool+brinsolamiid - silmatilgad, suspensioon - 5mg+10mg 1ml 5ml 6tk; 5mg+10mg 1ml 5ml 1tk

Estonya - Estonca - Ravimiamet

sia elvim - timolool+latanoprost - silmatilgad, lahus - 5mg+50mcg 1ml 2.5ml 1tk

Estonya - Estonca - Ravimiamet

sia elvim - dutasteriid - pehmekapsel - 0,5mg 30tk

Estonya - Estonca - Ravimiamet

stada arzneimittel ag - posakonasool - gastroresistentne tablett - 100mg 24tk; 100mg 60tk; 100mg 96tk

Estonya - Estonca - Ravimiamet

sia elvim - travoprost - silmatilgad, lahus - 40mcg 1ml 2.5ml 1tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

stada arzneimittel ag - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.